Premier Health First in Dayton Region to Offer Early Access to Promising Investigational Pancreatic Cancer Therapy

DAYTON, OH – Premier Health is offering eligible patients with advanced pancreatic cancer access to daraxonrasib, an investigational targeted therapy that has shown promising results in clinical studies and is generating significant interest among oncology specialists. 

Through a national Expanded Access Program (EAP), Premier Health is currently providing eligible patients access to daraxonrasib before potential FDA approval and broader commercial availability. Daraxonrasib is an oral therapy designed to target specific genetic mutations associated with tumor growth in many pancreatic cancers. 

In May 2026 published clinical studies, investigators reported encouraging results, including improved survival outcomes among eligible patients. 

"Pancreatic cancer has long been one of the most challenging cancers we treat," said Tarek M. Sabagh, MD, oncologist and chair of Premier Health Cancer Institute. "Because the disease is often diagnosed after it has already spread, treatment options can be limited. For many years, advances have been incremental. That is why the oncology community is paying close attention to therapies such as daraxonrasib." 

The drug has not yet received FDA approval. However, the Expanded Access Program allows physicians to provide the investigational treatment to qualifying patients while regulatory review continues. Under the program, daraxonrasib is administered under strict clinical oversight. Patients are carefully evaluated to determine whether they meet eligibility requirements based on their diagnosis and treatment history. 

Premier Health's participation in the Expanded Access Program reflects its commitment to bringing innovative cancer treatments and clinical advancements to patients throughout southwest Ohio. 

"For patients and families confronting pancreatic cancer, time matters," said Amanda Musser, system vice president of Premier Health Cancer Institute. "Every advance that gives patients and families more choices and potentially more time is meaningful. Providing access to this investigational therapy close to home means eligible patients can explore emerging treatment options without leaving the region." 

Patients interested in learning whether they may qualify for treatment through the Expanded Access Program should contact Premier Health's Office of Clinical Trials at (937) 915-2515.

About Premier Health

As a private, nonprofit academic health system, Premier Health takes pride in serving the residents of Southwest Ohio through a comprehensive and coordinated approach to health care delivery. Guided by its mission- We care. We teach. We innovate. We serve. – the system advances community well-being by integrating compassionate care with education, research, and innovation. Through its academic affiliation with Wright State University and the Boonshoft School of Medicine, Premier Health supports medical education, clinical research, and the development of the region’s future health care workforce. As one of the largest comprehensive health systems in the region, Premier Health provides advanced, high-quality care close to home through Miami Valley Hospital—home to the region’s only adult Level I Trauma Center—along with its North and South campuses, Atrium Medical Center, Upper Valley Medical Center, more than 130 outpatient and physician locations, and CompuNet Clinical Laboratories and Fidelity Health Care, which deliver coordinated clinical laboratory and home health services across the continuum.

More News from Middletown

• Landsman, Along With Two Others Leadz Legislation to Invest in Quality Early Childhood Education Congressional members Landsman (D-OH-01), Jahanna Hayes (D-CT-05), and Zoe Lofgren (D-CA-18) introduced legislation to invest in and improve the Head Start program.
• There’s a Fungus Among Us A surprising array of fungi are appearing this summer.